Thermo Fisher Scientific (TMO) PT Raised to $610 at Deutsche Bank

Deutsche Bank analyst Justin Bowers raised the price target on Thermo Fisher Scientific (NYSE: TMO) to $610.00 (from $600.00) while maintaining a Buy rating.

The analyst comments "Messaging around bioprocessing was concise but positive, as order growth and book-to-bill continue to trend higher. We are increasing our PT to $610 (from $600) based on our increased 2025 EPS. Downside risks: Slowing demand for bioprocessing; inability to backfill C19 business; business interruption due to geopolitical instability or quarantine policies."

You May Also Be Interested In

• Quest Diagnostics (DGX) PT Raised to $245 at UBS
• Arcus Biosciences (RCUS) PT Raised to $40 at Truist Securities
• Ionis Pharmaceuticals (IONS) PT Lowered to $54 at BMO Capital Post Pelacarsen Failure